<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Factor XI Inhibitors &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/factor-xi-inhibitors/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 22 Jan 2025 22:20:08 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Factor XI Inhibitors &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Research Findings: Anticoagulant Medication Decreases Bleeding Incidents in Atrial Fibrillation Patients</title>
		<link>https://bioengineer.org/research-findings-anticoagulant-medication-decreases-bleeding-incidents-in-atrial-fibrillation-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 22 Jan 2025 22:20:08 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Abelacimab]]></category>
		<category><![CDATA[Atrial Fibrillation]]></category>
		<category><![CDATA[AZALEA-TIMI 71 Study]]></category>
		<category><![CDATA[Bleeding Risk Reduction]]></category>
		<category><![CDATA[Factor XI Inhibitors]]></category>
		<guid isPermaLink="false">https://bioengineer.org/research-findings-anticoagulant-medication-decreases-bleeding-incidents-in-atrial-fibrillation-patients/</guid>

					<description><![CDATA[A Breakthrough in Anticoagulant Therapy for Atrial Fibrillation: The Promise of Factor XI Inhibitors Atrial fibrillation (AF) represents one of the most prevalent cardiac arrhythmias, impacting millions of individuals worldwide. Patients diagnosed with AF are commonly prescribed anticoagulants to mitigate the elevated risk of stroke associated with this condition. However, a substantial number of patients [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">234562</post-id>	</item>
	</channel>
</rss>
